A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
Clinical trial NCT05243342 · COMPLETED
Trial details
- NCT number
- NCT05243342
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-28
- Primary completion
- 2024-07-10
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.